{"id":"W3175516050","doi":"10.1016/j.eclinm.2021.100940","title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial","year":2021,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"Boehringer Ingelheim","keywords":"Medicine; Erlotinib; Afatinib; Lung cancer; Internal medicine; Erlotinib Hydrochloride; Hazard ratio; Adverse effect; Surgery; Oncology; Cancer; Epidermal growth factor receptor; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006584895,0.001823167,0.003756027,0.0004766224,0.000358274,0.00168428,0.001309558,0.001782938,0.007047449],"category_scores_gemma":[0.006137882,0.0005956485,0.008071611,0.0004879852,0.0008199067,0.001569371,0.0007262892,0.003375703,0.001105456],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001583518,"about_ca_system_score_gemma":0.001550838,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009150665,"about_ca_topic_score_gemma":0.003620429,"domain_scores_codex":[0.9959925,0.002852698,0.000227685,0.0003409175,0.0002329356,0.0003532456],"domain_scores_gemma":[0.9971938,0.0009500594,0.0008372084,0.000259198,0.0002253666,0.000534303],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9804033,0.001026455,0.001076974,0.0007371809,0.004371813,0.00003803512,0.00004348132,0.0006552076,0.001079167,0.0001119183,0.001266522,0.009189952],"study_design_scores_gemma":[0.944083,0.04615368,0.004007763,0.00007694166,0.00292226,0.00008317758,0.00003566271,0.0007582837,0.0003391751,0.0004043792,0.0011056,0.00003003694],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.967654,0.01538499,0.001356304,0.001967888,0.0008093756,0.004053554,0.004851384,0.0002508529,0.003671752],"genre_scores_gemma":[0.9860183,0.00219133,0.001297712,0.00119628,0.0003824972,0.002809578,0.003923845,0.00004755211,0.002132966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007047449,"threshold_uncertainty_score":0.03482467,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03098304793494916,"score_gpt":0.3744962889247768,"score_spread":0.3435132409898276,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}